Clinical trials: Essential Hypertension.
Essential Hypertension
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.
- Trial name
- NCT06282549
- Testing
- Telmisartan/Amlodipine/Chlorthalidone(Truset)
- Where
- 5 sites in South Korea
- Volunteers
- 1,219 people
- Sponsor
- Yuhan Corporation
Essential Hypertension
Perindopril Amlodipine for the Treatment of Hypertension
The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension.
- Trial name
- PATH (NCT01556997)
- Testing
- XOMA 985, Amlodipine Besylate, Perindopril Erbumine
- Where
- 48 sites in United States
- Volunteers
- 837 people
- Sponsor
- Symplmed Pharmaceuticals LLC
Hypertension
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
- Trial name
- NCT00631917
- Testing
- Aliskiren, Ramipril
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 774 people
- Sponsor
- Novartis
Essential Hypertension, Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group…
- Trial name
- FIESTA (NCT03338426)
- Testing
- Fimasartan 120mg, Atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 133 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Blood Pressure, High
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension
The purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.
- Trial name
- NCT00355589
- Testing
- Ramipril and hydrochlorothiazide
- Where
- 60 sites in United States
- Sponsor
- Pfizer
HYPERTENSION, HYPERCHOLESTEROLEMIA
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
This 10-12 week study will provide data on the safety and efficacy of using 320 valsartan and 80 mg simvastatin together compared to using either one alone in lowering blood pressure and LDL cholesterol.
- Trial name
- NCT00171093
- Testing
- valsartan + simvastatin
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Novartis
Hypertension
Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)
This study will determine whether using losartan and amlodipine together will be non-inferior in lowering blood pressure than amlodipine alone.
- Trial name
- NCT01277822
- Testing
- Losartan (+) amlodipine, Amlodipine camsylate
- Volunteers
- 334 people
- Sponsor
- Organon and Co
Essential Hypertension
Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension
This study is designed to evaluate the additional efficacy and safety of olmesartan medoxomil/hydrochlorothiazide in the treatment of Chinese patients with mild to moderate essential hypertension, who fail to attain the blood…
- Trial name
- NCT00872586
- Testing
- olmesartan medoxomil + hydrochlorothiazide, olmesartan medoxomil
- Where
- 8 sites in China
- Volunteers
- 304 people
- Sponsor
- Daiichi Sankyo
Hypertension
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
This study will compare the safety and efficacy of initial combination treatment with aliskiren + amlodipine to sequential add-on treatment strategies with aliskiren or amlodipine in patients with hypertension.
- Trial name
- ACCELERATE (NCT00797862)
- Testing
- Amlodipine, hydrochlorothiazide, Aliskiren
- Where
- 10 sites in Canada, Costa Rica and 8 more
- Volunteers
- 1,254 people
- Sponsor
- Novartis
Hypertension
A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension
The purpose of this study is to compare the efficacy of the Egalet® controlled release formulation to an immediate release Carvedilol tablet.
- Trial name
- NCT00444834
- Testing
- Carvedilol
- Where
- 2 sites in Denmark
- Volunteers
- 14 people
- Sponsor
- Egalet Ltd
Hypertension
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of amlodipine(5mg or 10mg) and losartan (50 mg or 100 mg), amlodipine and losartan alone in reducing blood pressure.
- Trial name
- NCT00942344
- Testing
- Amlodipine plus Losartan, Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 320 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Primary Hypertension
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.
- Trial name
- NCT00882947
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Bayer
Essential Hypertension
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
QGC001/1QG1 is a Phase I "first time in man" study aiming to determine the overall safety and tolerability of single ascending oral doses of QGC001 in healthy male subjects compared to placebo, as well as the pharmacokinetics of…
- Trial name
- NCT01900171
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Essential Hypertension
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.
- Trial name
- NCT00846365
- Testing
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
- Where
- 80 sites in United States, Chile and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Takeda
Hypertension
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
- Trial name
- NCT00696436
- Testing
- Azilsartan medoxomil, Valsartan, Olmesartan
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,291 people
- Sponsor
- Takeda
Essential Hypertension
Safety Study of RMJH-111b to Treat Essential Hypertension
The purpose of this study was to evaluate the safety of RMJH-111b, including how well it is tolerated, and the effect of RMJH-111b on blood pressure in subjects with hypertension.
- Trial name
- NCT02822222
- Testing
- Magnesium citrate, tribasic anhydrous soft gelatin capsule
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RMJ Holdings, LLC
Essential Hypertension
Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)
Study objective: 1. To evaluate the antihypertensive efficacy, safety and tolerability of the drug after the oral administration of BR-A-657•K at 20~180mg for 4 weeks to patients with essential hypertension. 2.
- Trial name
- Fimasartan (NCT00937651)
- Testing
- Fimasartan (BR-A-657•K) 20 mg, Fimasartan (BR-A-657•K) 60 mg, Fimasartan (BR-A-657•K) 180 mg
- Volunteers
- 81 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension…
- Trial name
- NCT06041529
- Testing
- Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
- Where
- 15 sites in South Korea
- Volunteers
- 198 people
- Sponsor
- Yuhan Corporation
Hypertension
Irbesartan and Amlodipine Combination in Controlling Blood Pressure
The primary objective is to compare the extent of reduction of mean Seated Diastolic Blood Pressure (SeDBP) at the end of 8 weeks between each Fixed Dose Combination (FDC), its individual constituents administered as monotherapy…
- Trial name
- I-COMBO (NCT00950066)
- Testing
- IRBESARTAN (SR47436), Amlodipine, Irbesartan / Amlodipine
- Where
- 4 sites in India, Philippines and 2 more
- Volunteers
- 270 people
- Sponsor
- Sanofi
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
The objective of this clinical trial is to evaluate the efficacy and safety of BR1015 Combination therapy group in comparison with Fimasartan monotherapy group at Week 8 for essential hypertension patients who do not adequately…
- Trial name
- NCT05878561
- Testing
- Fimasartan + Indapamide
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd